- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07942168
Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma (SARCOGYN)
Phase II Randomized Trial of Doxorubicin Plus Dacarbazine Versus Standard Doxorubicin as First-Line Therapy for Metastatic Uterine Leiomyosarcoma or t Uterine Leiomyosarcoma Recurrent After Surgical Treatment
The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Leiomyosarcoma (LMS) represents 10-20% of soft-tissue sarcomas and has a poor prognosis in advanced stages. Retrospective multicenter data suggest that the doxorubicin plus dacarbazine combination improves progression-free survival (9.2 vs. 4.8 months) and response rates (30.9% vs. 25.6%) over doxorubicin alone in the advanced disease setting; however, this has never been investigated in randomized trials. This single-center, open-label trial compares doxorubicin plus dacarbazine with doxorubicin alone as first-line systemic therapy in patients with metastatic uterine leiomyosarcoma or with disease recurrence after prior surgical treatment.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Alexander Anokhin, PhD
- Numéro de téléphone: +7-915-518-85-00
- E-mail: anokhinaleks@mail.ru
Lieux d'étude
-
-
-
Moscow, Russie
- Recrutement
- Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
-
Contact:
- Alexander Anokhin, PhD
- Numéro de téléphone: +7-915-518-85-00
- E-mail: anokhinaleks@mail.ru
-
Contact:
- Alexey Rumyantsev, PhD
- Numéro de téléphone: +7-499-324-10-87
- E-mail: a.rumyantsev@ronc.ru
-
Chercheur principal:
- Alexander Anokhin, PhD
-
Sous-enquêteur:
- Alexey Rumyantsev, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
- Morphologically verified uterine leiomyosarcoma
- Age 18 to 70 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Metastatic disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease
- No prior systemic anticancer therapy
- No contraindications to doxorubicin and dacarbazine
- Metastatic or recurrent disease confirmed by contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis (contrast-enhanced magnetic resonance imaging (MRI) of the pelvis is allowed)
- Measurable disease on CT or MRI prior to randomization
- Consent to treatment at N.N. Blokhin National Medical Research Center of Oncology
- Consent to the proposed chemotherapy regimen
- Adequate bone marrow function: absolute neutrophil count ≥1.5×10⁹/L, platelets ≥100×10⁹/L
- Adequate liver function: bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
- Adequate cardiac function: satisfactory left ventricular systolic function
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Doxorubicin
Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Autres noms:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Autres noms:
|
|
Expérimental: Doxorubicin+Dacarbazine
Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days. |
Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line
Autres noms:
Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Autres noms:
Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
1-year progression-free survival (PFS)
Délai: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS) |
Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Survival
Délai: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
OS is defined as time from enrollment to death due to any cause |
Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)
|
|
Objective Response Rate
Délai: After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
Proportion of patients achieving complete or partial response per RECIST 1.1 |
After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days
|
|
incidence of Adverse events
Délai: During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Proportion of patients experiencing adverse events in each treatment arm |
During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs par type histologique
- Sarcome
- Tumeurs, tissus conjonctifs et mous
- Tumeurs, tissus musculaires
- Léiomyosarcome
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Azoles
- Hydrocarbures
- Hydrocarbures, cyclique
- Glucides
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glycosides
- Triazènes
- Imidazoles
- Anthracyclines
- Naphtacènes
- Aminoglycosides
- Daunorubicine
- Doxorubicine
- Dacarbazine
Autres numéros d'identification d'étude
- 08202511001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be shared because the informed consent form does not provide for sharing of data outside the research team.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .